Chinese expert consensus on the combined use of antiviral drugs for influenza

作者：Jing Yuan, Haimei Zhang, Rongrong Zou, Weizhen Weng, H. X. Bai, Jun Chen, Yutian Chong, Xilong Deng, Liang Fu, Yongshui Fu, Wen‐Jun Gao, Zuojiong Gong, Cheng-hui Huang, He Huang, Jia Huang, Jianning Jiang, Jiang Rongmeng, Yongfang Jiang, Linghua Li, Bingliang Lin, Xi Liu, Feng Lin, Jie Peng, Qingsong Qi, Bo Qin, Zhijun Qu, Fei Shi, Gang Wu, Tao Wu, Hui Wang, Lingwei Wang, Yan Wang, Fei Xiao, Feng Xu, Juan Xu, Kaijin Xu, Haipeng Zhu, Guanlin Zhou, Guangbin Chen, Hongzhou Lu · 发表于：BioScience Trends · 年份：2025 · DOI：10.5582/bst.2025.01292 · 被引用次数：3 · 研究领域：Influenza Virus Research Studies、Respiratory viral infections research、interferon and immune responses

Influenza is an acute respiratory infectious disease caused by influenza viruses, and it poses a serious threat to global public health. High-risk groups include the elderly, infants and young children, pregnant women, and patients with chronic underlying diseases. These groups are prone to developing severe illness after infection, which can lead to serious complications and even death. Early antiviral treatment is key to reducing the rate of severe illness and death. Currently, authoritative guidelines at home and abroad recommend early, single-agent antiviral therapy as the standard regimen. However, anti-influenza virus monotherapy has problems such as drug resistance and poor therapeutic effect. To address these problems, this consensus was developed by organizing experts from the departments of Infectious Diseases, Respiratory Medicine, Critical Care Medicine, and Pharmacy. These experts systematically sorted out domestic and international evidence on combined antiviral therapy for influenza and formulated expert recommendations on combined antiviral therapy for influenza in specific populations.